Frontiers in Oncology (May 2019)
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
- Nicolas Chapuis,
- Nicolas Chapuis,
- Nicolas Chapuis,
- Nicolas Chapuis,
- Nicolas Chapuis,
- Laury Poulain,
- Laury Poulain,
- Laury Poulain,
- Laury Poulain,
- Rudy Birsen,
- Rudy Birsen,
- Rudy Birsen,
- Rudy Birsen,
- Jerome Tamburini,
- Jerome Tamburini,
- Jerome Tamburini,
- Jerome Tamburini,
- Jerome Tamburini,
- Didier Bouscary,
- Didier Bouscary,
- Didier Bouscary,
- Didier Bouscary,
- Didier Bouscary
Affiliations
- Nicolas Chapuis
- INSERM U1016, Institut Cochin, Paris, France
- Nicolas Chapuis
- CNRS UMR8104, Paris, France
- Nicolas Chapuis
- Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
- Nicolas Chapuis
- Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
- Nicolas Chapuis
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Paris, France
- Laury Poulain
- INSERM U1016, Institut Cochin, Paris, France
- Laury Poulain
- CNRS UMR8104, Paris, France
- Laury Poulain
- Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
- Laury Poulain
- Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
- Rudy Birsen
- INSERM U1016, Institut Cochin, Paris, France
- Rudy Birsen
- CNRS UMR8104, Paris, France
- Rudy Birsen
- Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
- Rudy Birsen
- Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
- Jerome Tamburini
- INSERM U1016, Institut Cochin, Paris, France
- Jerome Tamburini
- CNRS UMR8104, Paris, France
- Jerome Tamburini
- Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
- Jerome Tamburini
- Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
- Jerome Tamburini
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France
- Didier Bouscary
- INSERM U1016, Institut Cochin, Paris, France
- Didier Bouscary
- CNRS UMR8104, Paris, France
- Didier Bouscary
- Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
- Didier Bouscary
- Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
- Didier Bouscary
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France
- DOI
- https://doi.org/10.3389/fonc.2019.00405
- Journal volume & issue
-
Vol. 9
Abstract
Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities which are applicable to acute myeloid leukemia (AML). Indeed, in addition to the IDH1/2-mutated AML model which established the proof-of-concept for specifically targeting metabolic adaptations in AML, several recent reports have expanded the scope of such strategies in these diseases. This review highlights recent findings on metabolic deregulation in AML and summarizes their implications in leukemogenesis.
Keywords
